<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neonatal diabetes mellitus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neonatal diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neonatal diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara E Pinney, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer A Sutter, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4198788734"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neonatal diabetes mellitus (DM) is characterized by the onset of persistent hyperglycemia within the first six months of life due to impaired insulin function and is frequently caused by a mutation in a single gene affecting pancreatic beta cell function.</p><p>The presentation, clinical manifestations, diagnosis, and evaluation for neonatal DM will be reviewed here. An overview of causes and management of neonatal hyperglycemia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia"</a>.)</p><p class="headingAnchor" id="H3992499902"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The terminology describing DM in the first year of life is somewhat confusing. Neonatal DM is the commonly used term to describe monogenic forms of DM that present during infancy. Although some patients present within the neonatal time period of the first 30 days of life, infants most often present within the first six months of life, and occasionally present up to 12 months of life [<a href="#rid1">1-3</a>]. In contrast, autoimmune type 1 diabetes is unlikely to present within the first six months of life. Therefore, the term neonatal DM, which is most commonly used in the literature and clinically, will be the term used throughout this topic and refers to patients up to one year of life who present with monogenic DM. (See  <a class="medical medical_review" href="/z/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents", section on 'Infants'</a> and  <a class="medical medical_review" href="/z/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H771902265"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>DM is a rare cause of neonatal and infantile hyperglycemia with reported incidence ranging from 1 in 90,000 to 160,000 live births [<a href="#rid4">4,5</a>]. Most infants who present with DM in the first six months of life will have a monogenic cause referred to as neonatal DM [<a href="#rid1">1</a>]. (See <a class="local">'Terminology'</a> above.)</p><p class="headingAnchor" id="H1920899806"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H1537237338"><span class="h2">Overview of gene mutations</span><span class="headingEndMark"> — </span>Neonatal DM is caused by a single mutation in one of several genes that are involved in the normal development and function of pancreatic beta cells including insulin production and secretion [<a href="#rid1">1</a>]. Clinical manifestations (transient versus permanent diabetes mellitus, extrapancreatic features), prognosis, and treatment depend upon the affected gene and the underlying pathogenesis [<a href="#rid2">2</a>].</p><p>Mutations that cause neonatal DM are a result of impaired insulin function due to one of the following mechanisms and affected genes [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal beta cell function affecting insulin production and secretion – <em>KCNJ11, ABCC8, INS, GCK, SLC2A2</em>, <em>SLC19A2</em>, <em>RFX6</em> [<a href="#rid6">6-15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta cell destruction due to cellular stress or autoimmunity – <em>INS, EIF2AK3, IER3IPI, FOXP3, WFS1, LRBA, STAT1, STAT3 </em>[<a href="#rid16">16-22</a>].      </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal pancreatic development (pancreatic aplasia or hypoplasia) –<em> PDX1</em> <em>(IPF1), PTF1A, HNF1B, RFX6, GATA4,</em> <em>GATA6, CNOT1, GLIS3, NEUROG3, NEUROD1, PAX6</em>,<em> NKX2-2, MNX1</em> [<a href="#rid23">23-34</a>].</p><p></p><p>The relative frequency of different genetic causes was determined in a large case series of 1020 patients diagnosed with neonatal DM before six months of age [<a href="#rid2">2</a>]. Comprehensive genetic testing identified causal mutation in more than 80 percent of cases. Mutations in <em>KCNJ11</em> and <em>ABCC8</em>, which encode for subunits of the ATP-sensitive potassium channel (K<sub>ATP</sub>) in the pancreatic beta cell, were the most common (n = 390) found in 46 percent of infants with neonatal diabetes from nonconsanguineous families and 12 percent of identified consanguineous families. Mutations in the gene that encodes insulin (<em>INS</em>) had similar rates of 10 percent in patients from nonconsanguineous and consanguineous families (n = 110). In consanguineous families, the most common genetic cause was a homozygous mutation in <em>EIF2AK3 </em>gene causing <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F226980&amp;token=87jLzclRwWxNoI%2BQq5Gg79lFnNP%2FKNHa4XEjzlRHOMdbchJ6ixS8GJkxDmDnoFHc&amp;TOPIC_ID=116267" target="_blank">Wolcott-Rallison syndrome</a> (OMIM#226980, n = 24 percent) (n = 76).</p><p>Although neonatal DM may also occur in preterm infants (gestational age &lt;37 weeks), it is more challenging to make a diagnosis in this group of patients. In a second case series, 146 of 750 infants with diabetes diagnosed before six months of age were born preterm [<a href="#rid35">35</a>]. A genetic etiology was identified in 97/146 (66 percent) preterm infants compared with 501/604 (83 percent) term infants [<a href="#rid35">35</a>]. <em>KCNJ11</em> gene mutations were less common in preterm infants.</p><p class="headingAnchor" id="H1697111268"><span class="h2">Phenotypic expression</span><span class="headingEndMark"> — </span>Gene mutations that cause neonatal DM are expressed as one of the following clinical subtypes [<a href="#rid2">2,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Transient diabetes mellitus (eg, due to <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600937%3Fsearch%3DDEND+syndrome%26highlight%3Dsyndromic+syndrome+dend&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrMTo9fs88QSD%2BBwnQJK6EdSr0CdMfW7MLx4M2jLJXUSHWYXs7kqXprUp8oS1KLZQgOlmZuat3ESBfbh6Pp7Zie&amp;TOPIC_ID=116267" target="_blank"><i>KCNJ11</i></a> or<em> </em><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600509%3Fsearch%3Dabcc8%26highlight%3Dabcc8&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyo2l1hNLV%2B7y263WIirUcIZRdZxJUTQEYqHu3NrKEMVgK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=116267" target="_blank"><i>ABCC8</i></a><em> </em>mutations or overexpression of the imprinted region of chromosome 6q24) – 20 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus responsive to oral sulfonylurea (eg, due to mutations of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600937%3Fsearch%3DDEND+syndrome%26highlight%3Dsyndromic+syndrome+dend&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrMTo9fs88QSD%2BBwnQJK6EdSr0CdMfW7MLx4M2jLJXUSHWYXs7kqXprUp8oS1KLZQgOlmZuat3ESBfbh6Pp7Zie&amp;TOPIC_ID=116267" target="_blank"><i>KCNJ11</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600509%3Fsearch%3Dabcc8%26highlight%3Dabcc8&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyo2l1hNLV%2B7y263WIirUcIZRdZxJUTQEYqHu3NrKEMVgK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=116267" target="_blank"><i>ABCC8</i></a>, which encode subunits of the K<sub>ATP </sub>channel) – 40 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Permanent isolated diabetes mellitus that requires lifelong insulin therapy (eg, due to mutations of <em>INS</em>) – 10 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Syndromic diabetes mellitus with extra-pancreatic features (eg, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F226980&amp;token=87jLzclRwWxNoI%2BQq5Gg79lFnNP%2FKNHa4XEjzlRHOMdbchJ6ixS8GJkxDmDnoFHc&amp;TOPIC_ID=116267" target="_blank">Wolcott-Rallison syndrome</a> due to mutations of <em>EIF2AK3</em>) – 10 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune diabetes in infancy associated with other manifestations of immune dysfunction due to rare monogenic mutations in genes important for immune function (eg, <em>FOXP3, LRBA, STAT1, STAT3 </em>mutations).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No genetic cause identified. </p><p></p><p class="headingAnchor" id="H2955891092"><span class="h3">Transient neonatal DM</span><span class="headingEndMark"> — </span>Twenty percent of patients who present with neonatal diabetes will ultimately be found to have transient neonatal DM that resolves in infancy (usually by 13 to 18 weeks of age) but may recur later in life [<a href="#rid1">1-3,36</a>]. In the previously mentioned large case series, 20 percent of the cohort had a genetic diagnosis of transient neonatal DM [<a href="#rid2">2</a>]. The underlying genetic defects included: </p><p class="bulletIndent1"><span class="glyph">●</span>Overexpression of the imprinted region of chromosome 6q24, which include the genes <em>PLAGL</em>, <em>HYMAI, </em>and<em> ZPF57</em> [<a href="#rid37">37-41</a>]. The overexpression of this region has been attributed to either a mutation in the zinc finger transcription factor ZPF57 leading to hypomethylation of the imprinted loci, or due to the duplication of 6q24 from either paternal uniparental disomy or an unbalanced duplication of the paternal chromosome 6 [<a href="#rid39">39-41</a>]. Of note, patients may develop hypoglycemia in later infancy or childhood after the initial hyperglycemic phase [<a href="#rid36">36</a>] and 50 percent of patients redevelop hyperglycemia in adulthood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activating mutations of either <em>KCNJ11 </em>or<em> ABCC8</em> that encode subunits of the K<sub>ATP </sub>channel, which are discussed below, can lead to both transient or permanent neonatal diabetes. For patients with these gene mutations, the continued need for therapeutic interventions determines whether diabetes is transient or permanent. (See <a class="local">'Sulfonylurea therapy'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Case reports of patients with mutations of <em>INS</em>, which encodes preproinsulin [<a href="#rid42">42-44</a>].</p><p></p><p class="headingAnchor" id="H3215906073"><span class="h3">Neonatal DM responsive to sulfonylurea</span><span class="headingEndMark"> — </span>Approximately 40 percent of patients with neonatal DM are responsive to sulfonylurea treatment caused by activating mutations of <em>KCNJ11</em> or <em>ABCC8</em>, which<em> </em>may result in either transient or permanent DM [<a href="#rid1">1-3</a>]. For most infants with these genetic mutations, oral sulfonylurea therapy is as effective as subcutaneous insulin in controlling hyperglycemia [<a href="#rid45">45-48</a>]. These mutations are the most common cause of neonatal DM and affect genes that encode subunits of the K<sub>ATP </sub>channel [<a href="#rid2">2</a>]. <em>KCNJ11</em> encodes the inner subunit (Kir6.2) of the K<sub>ATP </sub>channel, whereas <em>ABCC8 </em>encodes the outer subunit (SUR1). Mutations in these genes result in inappropriately open K<sub>ATP</sub> channels even in the presence of hyperglycemia. Without closure of the K<sub>ATP</sub> channels, the cell membrane is unable to depolarize and release insulin. (See <a class="local">'Sulfonylurea therapy'</a> below.)</p><p>K<sub>ATP</sub> channels are also found in the brain. Patients with permanent neonatal DM due to activating <em>KCNJ11</em> mutations may also present with varying degrees of neurodevelopmental and psychiatric difficulties [<a href="#rid49">49-54</a>]. The combination of the most severe developmental delays and epilepsy is referred to as DEND (developmental delay, epilepsy, neonatal diabetes) syndrome. Many but not all studies suggest that early diagnosis and treatment with a sulfonylurea may improve neurologic outcome depending on the specific mutation involved [<a href="#rid55">55-57</a>]. </p><p>By contrast, inactivating mutations of <em>KCNJ11</em> or <em>ABCC8</em> are important causes of congenital hyperinsulinism, which is characterized by persistent hyperinsulinemic hypoglycemia. (See  <a class="medical medical_review" href="/z/d/html/5810.html" rel="external">"Pathogenesis, clinical presentation, and diagnosis of congenital hyperinsulinism"</a>.)</p><p class="headingAnchor" id="H1673368429"><span class="h3">Permanent isolated neonatal DM requiring insulin</span><span class="headingEndMark"> — </span>Approximately 40 to 50 percent of infants with permanent neonatal DM will require lifelong treatment with insulin. Mutations of <em>INS</em>, which encodes preproinsulin, account for 10 percent of neonatal DM cases and up to 20 percent of those with permanent neonatal DM [<a href="#rid2">2,14</a>]. Patients with mutations of <em>INS</em> have isolated DM and will require lifelong insulin therapy. In these patients, mutations in the coding regions of the gene lead to misfolding of the insulin protein, which accumulates in subcellular compartments and contributes to beta cell death [<a href="#rid12">12,13</a>]. Noncoding <em>INS</em> mutations in the promoter region lead to changes in chromatin accessibility and transcription factor binding and decreased <em>INS </em>gene transcription [<a href="#rid58">58</a>].</p><p>In addition, approximately 10 percent of patients with <em>KCNJ11</em> mutations causing neonatal DM are not responsive to treatment with sulfonylureas and must be treated with insulin [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H3953951351"><span class="h3">Neonatal DM associated with genetic syndromes</span><span class="headingEndMark"> — </span>DM is a clinical feature of many different syndromes that present during infancy caused by mutations in over 17 genes [<a href="#rid2">2</a>]. Syndromic causes of neonatal DM account for approximately 10 percent of neonatal DM cases due to a variety of pathogenetic mechanisms including abnormal pancreatic development, beta cell destruction, and impaired beta cell function and severe insulin resistance syndromes. </p><p>The most common syndrome presenting with neonatal DM is <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F226980&amp;token=87jLzclRwWxNoI%2BQq5Gg79lFnNP%2FKNHa4XEjzlRHOMdbchJ6ixS8GJkxDmDnoFHc&amp;TOPIC_ID=116267" target="_blank">Wolcott-Rallison syndrome</a> (OMIM#226980), an autosomal recessive disorder. It is caused by mutations in <em>EIF2A</em>, which encodes the<em> </em>translation initiation factor 2-alpha kinase 3 (important in the regulation of endoplasmic reticulum) [<a href="#rid16">16</a>]. It occurs in almost 30 percent of cases with consanguineous families [<a href="#rid2">2</a>]. Other features include hepatic dysfunction and skeletal dysplasia. </p><p>Other more rare syndromes that present with neonatal DM include [<a href="#rid1">1,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), a rare X-linked disorder is caused by mutations to the gene that encodes the transcription factor FOXP3. (See  <a class="medical medical_review" href="/z/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F138160%3Fsearch%3Dfanconi-bickel+syndrome%26highlight%3Dbickel+fanconibickel+syndrome+fanconi+syndromic&amp;token=tEpDslnpc0F0kICl%2Fz7sFakATHRTAlgxtyC0kXeRiun%2Fdnz4Iv5neUgZTu%2B5Lgh8vrg9jaVYQKuv5HVDjvq%2BvD0T5Lwq3HW%2BGWmuAHQtHq55TovTsuH%2FxGG5gOAdt9wC&amp;TOPIC_ID=116267" target="_blank">Fanconi-Bickel syndrome</a> (OMIM#138160), an autosomal recessive disorder, is caused by mutations of <em>SLC2A2 </em>(<em>GLUT2</em>)<em>. </em>Other features include liver dysfunction and hypergalactosemia. (See  <a class="medical medical_review" href="/z/d/html/2914.html" rel="external">"Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency", section on 'GLUT2 deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F249270%3Fsearch%3Drogers+syndrome%26highlight%3Dsyndromic+roger+syndrome&amp;token=tEpDslnpc0F0kICl%2Fz7sFb92woTTVjFLTfan5WnpViUIZRAXfmmAdEdxBK4Mh8ClbTpdIkXThHfyxcDpjwT9yx%2FEi9uRlzj4Pk3MV2GAUXJwtjl79ohLHQyjSH9zBZer&amp;TOPIC_ID=116267" target="_blank">Rogers syndrome</a> (OMIM#249270), an autosomal recessive disorder, is caused by mutations of <em>SLC19A2</em>. Other features include thiamine-responsive megaloblastic anemia and sensorineural hearing loss. (See  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Thiamine-responsive megaloblastic anemia (SLC19A2 mutation)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F222300%3Fsearch%3Dwolfram+syndrome%26highlight%3Dsyndromic+syndrome+wolfram&amp;token=tEpDslnpc0F0kICl%2Fz7sFRJcCUASk49Ds%2FQL7Yc%2FaUXWxgff3FJ48tdnLOifGthtuOJiOKJsHo2aoIUsuxqEjKHLn8CqPawG5yy5WwkKfzkAVWXDD3AjPsUBu0PqEVrI&amp;TOPIC_ID=116267" target="_blank">Wolfram syndrome</a> (OMIM#222300), an autosomal recessive disorder, is caused by mutations of <em>WFS1 </em>[<a href="#rid19">19</a>]. Other features include diabetes insipidus, optic atrophy, and deafness leading to an alternative acronym of DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness) syndrome. (See  <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">"Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Wolfram syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Donohue syndrome, Rhabson-Mendenhall syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F147670%3Fsearch%3Dinsr%26highlight%3Dinsr&amp;token=tEpDslnpc0F0kICl%2Fz7sFYR8Q1aXDxBReNYTLBTBwCTvhWnkV71LwifvtaO9E%2B2FdyiJMKFI43sEWTEzpjdrSQ%3D%3D&amp;TOPIC_ID=116267" target="_blank">INSR</a> mutations) – Mutations of <em>INSR</em>, which encodes the insulin receptor, result in severe insulin resistance syndromes presenting with post-prandial hyperglycemia, fasting hypoglycemia, poor linear growth, and impaired muscle and adipose development [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H2529357294"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H686261833"><span class="h2">Presentation</span><span class="headingEndMark"> — </span>Due to the genetic heterogeneity underlying neonatal DM, the clinical presentation of affected infants varies from incidentally identified asymptomatic hyperglycemia to severe dehydration and diabetic ketoacidosis (DKA) [<a href="#rid1">1,2,4</a>].</p><p>Clinical manifestations include [<a href="#rid1">1,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Small for gestational age – Frequently neonatal DM presents prenatally with intrauterine growth restriction due to a deficiency of functional insulin, which is an in-utero growth factor. Catch-up growth is observed when there is subsequent appropriate postnatal treatment resulting in euglycemia [<a href="#rid1">1,60,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor postnatal growth (ie, failure to thrive) for infants who do not receive appropriate therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyuria due to hyperglycemia and glucosuria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic ketoacidosis (DKA) – Infants with neonatal DM are at risk for dehydration and electrolyte abnormalities due to urinary losses and acidosis due to ketogenesis. However, the signs and symptoms of DKA in infants are nonspecific and include irritability, lethargy, tachypnea, and evidence of hypovolemia (eg, sunken eyes and fontanels). The frequency of DKA at presentation varies and is dependent on the specific underlying genetic disorder. DKA is reported to occur in approximately 30 percent of patients with mutations of <em>INS </em>(isolated diabetes mellitus requiring insulin) and ranges from 30 to 75 percent for those with mutations of either <em>KCNJ11 </em>or<em> ABCC8</em> (DM responsive to sulfonylurea) [<a href="#rid4">4,6</a>]. Patients with transient DM due to overexpression of <em>6q24</em> typically do not present with DKA [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">"Diabetic ketoacidosis in children: Clinical features and diagnosis", section on 'Signs and symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malabsorptive diarrhea – In some cases, pancreatic exocrine function may be impaired, resulting in malabsorptive diarrhea even in infants without pancreatic agenesis or hypoplasia [<a href="#rid29">29,62,63</a>]. Pancreatic exocrine insufficiency has been described in neonatal DM due to mutations in <em>NEUROG3</em> and <em>PDX1 </em>[<a href="#rid23">23,24,28,29</a>].</p><p></p><p class="headingAnchor" id="H528772075"><span class="h2">Extra-pancreatic findings</span><span class="headingEndMark"> — </span>Nonpancreatic findings are commonly seen in association with neonatal DM. They may be helpful in determining the underlying genetic mutation (see <a class="local">'Neonatal DM associated with genetic syndromes'</a> above) and include:  </p><p class="bulletIndent1"><span class="glyph">●</span>Skeletal abnormalities – <em>EIF2A</em> [<a href="#rid16">16,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic dysfunction – <em>EIF2A</em>, <em>SLC2A2</em> [<a href="#rid16">16,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optic abnormalities – <em>WFS1</em>,<em> PAX6</em> [<a href="#rid19">19,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deafness – <em>WFS1</em>,<em> SLC19A2 </em>[<a href="#rid19">19,64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothyroidism – <em>GLIS3 </em>[<a href="#rid26">26</a>] (see  <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism", section on 'Thyroid dysgenesis'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac abnormalities – <em>GATA4</em>, <em>GATA6</em> [<a href="#rid27">27,65</a>] (see  <a class="medical medical_review" href="/z/d/html/5754.html" rel="external">"Isolated atrial septal defects (ASDs) in children: Classification, clinical features, and diagnosis", section on 'Genetic disorders'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polycystic kidney disease – <em>HNF-1 beta</em> [<a href="#rid30">30</a>] (see  <a class="medical medical_review" href="/z/d/html/6083.html" rel="external">"Renal hypodysplasia", section on 'Genetic disorders'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune dysregulations – <em>IPEX</em>, <em>STAT1, STAT3, LRBA </em>[<a href="#rid20">20-22</a>]<em> </em>(see  <a class="medical medical_review" href="/z/d/html/3924.html" rel="external">"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic abnormalities and neurodevelopment impairment – <em>KCNJ11, NEUROD1, PTF1A, IER3IP1, CNOT1</em> [<a href="#rid6">6,25,28,33,34,64,66</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>KCNJ11</em> mutations can be associated with severe developmental delay, epilepsy, muscle weakness, and dysmorphic features [<a href="#rid6">6</a>]. These findings are also known as the DEND (developmental delay, epilepsy, neonatal diabetes) syndrome [<a href="#rid67">67</a>]. (See <a class="local">'Neonatal DM responsive to sulfonylurea'</a> above.) </p><p></p><p class="headingAnchor" id="H203221955"><span class="h2">Course</span><span class="headingEndMark"> — </span>In 20 percent of cases, neonatal DM spontaneously resolves prior to 18 months of age. However, there is often a recurrence of hyperglycemia in adolescence or adulthood. (See <a class="local">'Transient neonatal DM'</a> above.)</p><p>The remaining patients have a permanent disorder and will require lifelong medication either with oral sulfonylurea therapy and/or insulin. (See <a class="local">'Neonatal DM responsive to sulfonylurea'</a> above.) </p><p class="headingAnchor" id="H498940917"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Making a diagnosis of neonatal DM in infants &lt;6 months of age is challenging. A clinical diagnosis of DM is made for infants who have persistent insulin-dependent hyperglycemia beyond three days of life with blood glucose levels &gt;200 mg/dL and in whom alternative causes for elevated blood glucose levels have been excluded. For neonates and infants with DM, neonatal DM due to a monogenic etiology is confirmed when genetic testing identifies a causative gene mutation. (See <a class="local">'Genetic testing'</a> below and <a class="local">'Terminology'</a> above.)</p><p class="headingAnchor" id="H2785522724"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>For infants with persistent hyperglycemia, the following diagnostic evaluation is performed to exclude other causes of neonatal hyperglycemia and to differentiate monogenic neonatal DM from polygenic autoimmune type 1 DM. Further genetic testing is performed for infants with a clinical diagnosis of neonatal DM to determine the causative gene mutation.</p><p class="bulletIndent1"><span class="glyph">●</span>Review of history:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Is there any evidence of another cause of hyperglycemia (see <a class="local">'Differential diagnosis'</a> below)?</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Medications associated with elevated blood glucose levels (eg, corticosteroids, beta-adrenergic agents)? If so, consider discontinuation if possible.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Signs of sepsis?</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Excessive glucose administration through parenteral nutrition?</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Is there any history of diarrhea or loose fatty stools suggesting pancreatic exocrine functional impairment? If so, consider obtaining fecal elastase measurement, as low values suggest pancreatic exocrine insufficiency. (See  <a class="medical medical_review" href="/z/d/html/117487.html" rel="external">"Approach to chronic diarrhea in neonates and young infants (&lt;6 months)", section on 'Stool testing'</a> and  <a class="medical medical_review" href="/z/d/html/4779.html" rel="external">"Exocrine pancreatic insufficiency", section on 'Fecal elastase-1'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient is on parenteral nutrition, review the rate of glucose infusion. If it is greater than 8 mg/kg per minute, decrease the glucose infusion rate initially to a rate of 6 mg/kg per min if possible and evaluate the subsequent blood glucose level to see if it remains elevated. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Lowering the GIR'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory evaluation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain blood cultures to rule out sepsis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum C peptide and insulin level to determine endogenous insulin production.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessment for acidosis (blood gas) and ketones (beta-hydroxybutyrate) to identify infants with diabetic ketoacidosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune panel of antibodies associated with type 1 diabetes – Antibodies to glutamic acid decarboxylase (GAD), islet cell, insulin, the tyrosine phosphatases (insulinoma-associated protein 2 [IA-2] and IA-2 beta), and zinc transporter (ZnT8) generally distinguishes autoimmune type 1 diabetes from monogenic neonatal DM. However, these markers are rarely positive in infants less than 12 months of age. Nevertheless, we obtain an autoimmune panel in infants between 6 to 12 months that includes these antibodies as the presence of any of these autoantibodies is indicative of type 1 diabetes. (See  <a class="medical medical_review" href="/z/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents", section on 'Distinguishing type 1 from type 2 diabetes'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HbA1C is not recommended to diagnose DM in infants &lt;6 months of age because neonates have a high concentration of fetal hemoglobin (HgbF) and therefore a lower concentration of hemoglobin A (HgbA) [<a href="#rid68">68</a>]. An elevated HbA1C &gt;6.5 percent in an infant &lt;6 months would still be consistent with a diagnosis of diabetes, but a normal HbA1C would not be reassuring if there is clinical suspicion of neonatal diabetes. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal ultrasound to determine the presence and size of the pancreas.</p><p></p><p class="headingAnchor" id="H3371089728"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Once the diagnosis of DM has been established in an infant less than 12 months of age, targeted genetic testing to confirm and identify a monogenic etiology is recommended as this can guide treatment recommendations. Genetic testing is cost-effective because management of a high proportion of patients is improved with identification of the underlying defect (eg, patients responsive to oral sulfonylurea therapy). We suggest using screening panels from commercial laboratories that include 15 to 20 candidate genes for neonatal DM, as a cost-effective approach for neonatal DM genetic testing. As bioinformatics support for whole exome sequencing and whole genome sequencing becomes more readily available and more cost-effective, this testing approach will supersede candidate gene testing for neonatal DM. The United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2Fall%2Flabs%2F%3Fterm%3Dall%255bsb%255d&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryxPkJNKdBG7Cjp%2BIy%2FGhtipAAnVnCaTlGFTRTeu4gikbarrJ%2F%2FS9AEolml3SOIfoE%3D&amp;TOPIC_ID=116267" target="_blank">National Center for Biotechnology Information (NCBI) genetic registry</a> lists test services in the United States and other select countries. </p><p class="headingAnchor" id="H781542803"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for neonatal hyperglycemia is broad and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Causes'</a>.)</p><p>For persistent hyperglycemia, DM is a diagnosis of exclusion. The most common causes of neonatal hyperglycemia are differentiated from DM as follows (see <a class="local">'Diagnostic evaluation'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis: Positive blood cultures</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parenteral nutrition – Reduction of glucose infusion rate to physiologic glucose requirements. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Lowering the GIR'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications – Discontinuation of hyperglycemic medications, including corticosteroids and beta adrenergic drugs (eg, <a class="drug drug_pediatric" data-topicid="13248" href="/z/d/drug information/13248.html" rel="external">dopamine</a>, <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, or <a class="drug drug_pediatric" data-topicid="12650" href="/z/d/drug information/12650.html" rel="external">norepinephrine</a>) once medically appropriate.</p><p></p><p class="headingAnchor" id="H3395450911"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H327258651"><span class="h2">Overview</span><span class="headingEndMark"> — </span>For infants with persistent hyperglycemia, initial management is directed towards correction of fluid and electrolyte abnormalities, and reduction of hyperglycemia by administration of intravenous insulin. Patients with mutations in <em>ABCC8</em> or <em>KCNJ11 </em>may respond to oral sulfonylurea therapy and not require insulin therapy. Patients with pancreatic exocrine deficiency will require pancreatic enzyme supplementation.</p><p>Management should be directed by a clinician with expertise in treating persistent hyperglycemia in neonates and infants.</p><p class="headingAnchor" id="H787085111"><span class="h2">Fluid and electrolyte management</span><span class="headingEndMark"> — </span>Infants with evidence of dehydration, and electrolyte abnormalities including acidosis should be initially managed in an intensive care unit with supportive measures for volume repletion with intravenous fluids and correction of electrolyte deficits with electrolyte replacement. If significant dehydration is present at diagnosis, fluid resuscitation should be initiated prior to the start of treatment with insulin. (See  <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a>.) </p><p class="headingAnchor" id="H111788625"><span class="h2">Insulin therapy</span></p><p class="headingAnchor" id="H2699728508"><span class="h3">Initial intravenous insulin</span><span class="headingEndMark"> — </span>The initial management of persistent hyperglycemia in patients less than 12 months of age is administration of a continuous infusion of intravenous (IV) insulin following fluid repletion, if needed. The starting dose varies between 0.01 to 0.05 units/kg per hour depending on the severity of presentation with regards to degree of hyperglycemia and presence of ketoacidosis [<a href="#rid3">3,69,70</a>]. Dosing is adjusted in small increments of 0.01 units/kg per hour with the goal to slowly decrease and maintain glucose levels between 100 and 200 mg/dL. Frequent blood glucose monitoring provided by continuous glucose monitoring or via handheld glucometer (initially hourly and then up to eight measurements per day) guides subsequent insulin dosing. Optimal management includes insulin dose adjustments based on blood glucose monitoring to avoid complications from hyperglycemia and hypoglycemia. Discussion on the details and administration of insulin therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Insulin therapy'</a>.) </p><p class="headingAnchor" id="H1746370923"><span class="h3">Subcutaneous insulin therapy</span><span class="headingEndMark"> — </span>After the infant is stable and has started oral feedings, subcutaneous insulin therapy can be started either through multiple daily injections or as a continuous subcutaneous insulin infusion (CSII) using an insulin pump. Adequate nutrition and subcutaneous insulin will allow for appropriate treatment of hyperglycemia and weight gain. However, administrating subcutaneous insulin in infants with neonatal diabetes is challenging as infants usually have little subcutaneous fat, require small doses of insulin, and are prone to the development of hypoglycemia. The smallest feasible subcutaneous dose of any insulin, including long-acting (glargine) without dilution, is 0.5 units [<a href="#rid3">3</a>]. As a result, dilution of insulin will often be needed for safe administration and consultation with an experienced pediatric pharmacist is recommended.</p><p>In our practice, we use CSII to administer insulin along with continuous glucose monitoring because an insulin pump can reliably deliver small doses of insulin (although dilution of the insulin may be needed due to the small size of the infant). CSII is started using basal insulin at a dose between 0.1 to 0.3 units per kg per day depending on the most recent intravenous needs and then titrated based on glucose control with a targeted range of 100 to 200 mg/dL. Correction insulin for preprandial glucose levels over 250 mg/dL may be needed [<a href="#rid3">3,70-74</a>]. Initially, neonates and young infants may not need additional bolus insulin for meals. As the infant grows and eating patterns change this need for prandial insulin may evolve.</p><p>Alternatively, multiple daily injections based on preprandial glucose levels can be used with a similar target glucose level of 100 to 200 mg/dL. When using multiple daily dosing, we prefer the use of rapid-acting analog insulins (<a class="drug drug_pediatric" data-topicid="12772" href="/z/d/drug information/12772.html" rel="external">insulin lispro</a>, aspart, or glulisine) given three to four times per day before a feed. A starting dose of 0.1 to 0.15 units per kg per dose is used when the pre-prandial glucose level is over 200 to 250 mg/dL. Alternatively, long-acting insulins such as glargine may be used at a dose of 0.2 to 0.4 unit/kg per day divided in one to two injections per day [<a href="#rid3">3,69,70</a>]. However, intermediate-acting insulins such as NPH should not be used as they have been associated with an increased risk for erratic control and hypoglycemia.</p><p class="headingAnchor" id="H1301039029"><span class="h2">Sulfonylurea therapy</span><span class="headingEndMark"> — </span>For patients with neonatal DM due to mutations in <em>ABCC8</em> or <em>KCNJ11</em>, observational data from large case series showed that treatment with oral sulfonylurea drugs at high doses (up to 2.5 mg/kg per day of <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> [glibenclamide]) effectively treated hyperglycemia and reduced or eliminated the need for insulin treatment for 80 to 90 percent of patients with these mutations [<a href="#rid3">3,45,47,48,75</a>]. As a result, we recommend oral sulfonylurea therapy for these patients. </p><p>The transition from insulin to sulfonylurea treatment should be conducted in an inpatient setting supervised by a clinician with expertise in managing infants with diabetes in order to avoid hypoglycemia because the insulin requirement can decrease rapidly once sulfonylurea treatment has been initiated. For neonatal DM due to mutations in <em>ABCC8</em> or <em>KCNJ11</em>, the relative doses of sulfonylurea used are much higher compared with doses used to treat patients with type 2 diabetes (0.2 mg/kg per day). Data suggest that the success rate of transfer to sulfonylureas is dependent on the specific mutation present and associated with earlier treatment [<a href="#rid48">48,75,76</a>].</p><p>Since the K<sub>ATP</sub> channels are also found in the brain, treatment with sulfonylurea drugs can effectively treat some of the neurological symptoms associated with mutations in <em>KCNJ11</em>. There is some evidence that earlier initiation of treatment improves neurological outcomes [<a href="#rid49">49,55,56,76</a>]. </p><p>Since the treatment approach in neonatal DM depends upon the genetic mutation, it is important to obtain expedited genetic testing as soon as the diagnosis of neonatal DM is made. After establishing euglycemia with insulin therapy, and in the absence of pancreatic hypoplasia/aplasia, consanguinity, or syndromic features, an empiric trial of sulfonylurea is suggested while awaiting the results of genetic testing or if genetic testing is not available, in consultation with a pediatric endocrinologist [<a href="#rid3">3,47,56</a>].</p><p class="headingAnchor" id="H1511339967"><span class="h2">Transient neonatal DM: Discontinuing therapy</span><span class="headingEndMark"> — </span>If an infant's genetic testing results are suggestive of diagnosis of transient neonatal diabetes, a trial to discontinue therapy may be indicated, with a slow wean of the hypoglycemic agent (insulin or sulfonylurea) with ongoing monitoring of glucose levels. If the infant can be successfully weaned off their therapy while maintaining normoglycemia, glucose levels are monitored every three to six months to detect any development of chronic hyperglycemia. In addition, infants diagnosed with 6q24 transient neonatal diabetes are at risk for hypoglycemia, which typically presents between 6 to 18 months of age [<a href="#rid36">36</a>], and blood sugar monitoring is imperative during this time period even after the infant has been successfully weaned from insulin. (See <a class="local">'Transient neonatal DM'</a> above.)</p><p class="headingAnchor" id="H2631811614"><span class="h2">Pancreatic enzyme and nutrient supplementation</span><span class="headingEndMark"> — </span>If the infant has pancreatic exocrine deficiency, pancreatic enzyme replacement similar to that used in patients with cystic fibrosis is required to maximize enteral calorie absorption. In addition, nutrient repletion including fat soluble vitamins may be required. (See  <a class="medical medical_review" href="/z/d/html/5885.html" rel="external">"Cystic fibrosis: Assessment and management of pancreatic insufficiency", section on 'Pancreatic enzyme replacement therapy'</a> and  <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues", section on 'Nutrient deficits and goals'</a>.)</p><p class="headingAnchor" id="H3715752110"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal diabetes mellitus (DM) is the commonly used term to describe monogenic forms of DM that typically present within the first 12 months of life. Although some patients present within the neonatal time period of the first 30 days of life, infants most often present with neonatal DM within the first six months of life, occasionally up to 12 months of life, and very rarely after 12 months of age. (See <a class="local">'Terminology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal DM is caused by one of more than 30 identified genetic mutations. (See <a class="local">'Overview of gene mutations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal DM is expressed as one of several clinical subtypes depending on the specific gene mutation and including transient DM, DM responsive to oral sulfonylurea, isolated permanent DM requiring lifelong insulin therapy, and neonatal DM associated with genetic syndromes also requiring lifelong insulin therapy. (See <a class="local">'Phenotypic expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants with neonatal DM can present with incidentally noted hyperglycemia or symptomatically with clinical findings of dehydration, low birth weight, failure to thrive, glucosuria, ketoacidosis, and osmotic diuresis. (See <a class="local">'Presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical diagnosis of neonatal DM is made for infants who have persistent insulin-dependent hyperglycemia beyond three days with blood glucose levels &gt;200 mg/dL and in whom alternative causes for elevated blood glucose levels have been excluded. The diagnosis is confirmed when genetic testing identifies a causative gene mutation. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnostic evaluation for neonatal DM focuses on exclusion of other causes of neonatal hyperglycemia including distinguishing monogenic neonatal DM from autoimmune type 1 DM. Further genetic testing is performed for infants with a clinical diagnosis of neonatal DM to determine the causative gene mutation. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis of neonatal DM is broad and includes type 1 DM, sepsis, hyperglycemia due to excessive glucose intravenous infusion, and hyperglycemia-inducing medications. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infants with persistent hyperglycemia including those with neonatal DM, management is initially directed towards correction of fluid and electrolyte abnormalities and reduction of hyperglycemia by the administration of a continuous infusion of intravenous insulin. After the infant is stable and has started oral feedings, subcutaneous insulin therapy can be started either through multiple daily injections or as a continuous subcutaneous insulin infusion using an insulin pump.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After stabilization on insulin therapy and in absence of pancreatic hypoplasia/aplasia, consanguinity or syndromic features, we suggest an empiric trial of oral sulfonylurea while awaiting genetic testing or if genetic testing is not available (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Management'</a> above and <a class="local">'Overview of gene mutations'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with neonatal DM due to mutations in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600937%3Fsearch%3DDEND+syndrome%26highlight%3Dsyndromic+syndrome+dend&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrMTo9fs88QSD%2BBwnQJK6EdSr0CdMfW7MLx4M2jLJXUSHWYXs7kqXprUp8oS1KLZQgOlmZuat3ESBfbh6Pp7Zie&amp;TOPIC_ID=116267" target="_blank"><i>KCNJ11</i></a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600509%3Fsearch%3Dabcc8%26highlight%3Dabcc8&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyo2l1hNLV%2B7y263WIirUcIZRdZxJUTQEYqHu3NrKEMVgK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=116267" target="_blank"><i>ABCC8</i></a>, we recommend treatment with sulfonylurea drugs (<a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> [glibenclamide]) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). This therapy may effectively treat hyperglycemia and reduce or eliminate the need for insulin treatment in 80 to 90 percent of patients with these mutations. (See <a class="local">'Sulfonylurea therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants with pancreatic exocrine deficiency may require pancreatic enzyme and nutrient supplementation similar to that used in patients with cystic fibrosis to ensure adequate growth. (See  <a class="medical medical_review" href="/z/d/html/5885.html" rel="external">"Cystic fibrosis: Assessment and management of pancreatic insufficiency", section on 'Pancreatic enzyme replacement therapy'</a> and  <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues", section on 'Nutrient deficits and goals'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rubio-Cabezas O, Ellard S. Diabetes mellitus in neonates and infants: genetic heterogeneity, clinical approach to diagnosis, and therapeutic options. Horm Res Paediatr 2013; 80:137.</a></li><li><a class="nounderline abstract_t">De Franco E, Flanagan SE, Houghton JA, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet 2015; 386:957.</a></li><li><a class="nounderline abstract_t">Lemelman MB, Letourneau L, Greeley SAW. Neonatal Diabetes Mellitus: An Update on Diagnosis and Management. Clin Perinatol 2018; 45:41.</a></li><li><a class="nounderline abstract_t">Letourneau LR, Carmody D, Wroblewski K, et al. Diabetes Presentation in Infancy: High Risk of Diabetic Ketoacidosis. Diabetes Care 2017; 40:e147.</a></li><li><a class="nounderline abstract_t">Grulich-Henn J, Wagner V, Thon A, et al. Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV). Diabet Med 2010; 27:709.</a></li><li><a class="nounderline abstract_t">Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350:1838.</a></li><li><a class="nounderline abstract_t">Gloyn AL, Cummings EA, Edghill EL, et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab 2004; 89:3932.</a></li><li><a class="nounderline abstract_t">Vaxillaire M, Populaire C, Busiah K, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004; 53:2719.</a></li><li><a class="nounderline abstract_t">Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355:456.</a></li><li><a class="nounderline abstract_t">Smith SB, Qu HQ, Taleb N, et al. Rfx6 directs islet formation and insulin production in mice and humans. Nature 2010; 463:775.</a></li><li><a class="nounderline abstract_t">Njølstad PR, Søvik O, Cuesta-Muñoz A, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001; 344:1588.</a></li><li><a class="nounderline abstract_t">Colombo C, Porzio O, Liu M, et al. Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest 2008; 118:2148.</a></li><li><a class="nounderline abstract_t">Støy J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A 2007; 104:15040.</a></li><li><a class="nounderline abstract_t">Edghill EL, Flanagan SE, Patch AM, et al. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008; 57:1034.</a></li><li><a class="nounderline abstract_t">Støy J, Steiner DF, Park SY, et al. Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene. Rev Endocr Metab Disord 2010; 11:205.</a></li><li><a class="nounderline abstract_t">Delépine M, Nicolino M, Barrett T, et al. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000; 25:406.</a></li><li><a class="nounderline abstract_t">Thornton CM, Carson DJ, Stewart FJ. Autopsy findings in the Wolcott-Rallison syndrome. Pediatr Pathol Lab Med 1997; 17:487.</a></li><li><a class="nounderline abstract_t">Senée V, Vattem KM, Delépine M, et al. Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. Diabetes 2004; 53:1876.</a></li><li><a class="nounderline abstract_t">Rigoli L, Lombardo F, Di Bella C. Wolfram syndrome and WFS1 gene. Clin Genet 2011; 79:103.</a></li><li><a class="nounderline abstract_t">Hwang JL, Park SY, Ye H, et al. FOXP3 mutations causing early-onset insulin-requiring diabetes but without other features of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatr Diabetes 2018; 19:388.</a></li><li><a class="nounderline abstract_t">Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 2014; 46:812.</a></li><li><a class="nounderline abstract_t">Johnson MB, De Franco E, Lango Allen H, et al. Erratum. Recessively Inherited LRBA Mutations Cause Autoimmunity Presenting as Neonatal Diabetes. Diabetes 2017;66:2316-2322. Diabetes 2018; 67:532.</a></li><li><a class="nounderline abstract_t">Stoffers DA, Zinkin NT, Stanojevic V, et al. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997; 15:106.</a></li><li><a class="nounderline abstract_t">Stoffers DA, Stanojevic V, Habener JF. Insulin promoter factor-1 gene mutation linked to early-onset type 2 diabetes mellitus directs expression of a dominant negative isoprotein. J Clin Invest 1998; 102:232.</a></li><li><a class="nounderline abstract_t">Sellick GS, Barker KT, Stolte-Dijkstra I, et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 2004; 36:1301.</a></li><li><a class="nounderline abstract_t">Senée V, Chelala C, Duchatelet S, et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet 2006; 38:682.</a></li><li><a class="nounderline abstract_t">D'Amato E, Giacopelli F, Giannattasio A, et al. Genetic investigation in an Italian child with an unusual association of atrial septal defect, attributable to a new familial GATA4 gene mutation, and neonatal diabetes due to pancreatic agenesis. Diabet Med 2010; 27:1195.</a></li><li><a class="nounderline abstract_t">Rubio-Cabezas O, Minton JA, Kantor I, et al. Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities. Diabetes 2010; 59:2326.</a></li><li><a class="nounderline abstract_t">Pinney SE, Oliver-Krasinski J, Ernst L, et al. Neonatal diabetes and congenital malabsorptive diarrhea attributable to a novel mutation in the human neurogenin-3 gene coding sequence. J Clin Endocrinol Metab 2011; 96:1960.</a></li><li><a class="nounderline abstract_t">Yorifuji T, Kurokawa K, Mamada M, et al. Neonatal diabetes mellitus and neonatal polycystic, dysplastic kidneys: Phenotypically discordant recurrence of a mutation in the hepatocyte nuclear factor-1beta gene due to germline mosaicism. J Clin Endocrinol Metab 2004; 89:2905.</a></li><li><a class="nounderline abstract_t">Yasuda T, Kajimoto Y, Fujitani Y, et al. PAX6 mutation as a genetic factor common to aniridia and glucose intolerance. Diabetes 2002; 51:224.</a></li><li><a class="nounderline abstract_t">Flanagan SE, De Franco E, Lango Allen H, et al. Analysis of transcription factors key for mouse pancreatic development establishes NKX2-2 and MNX1 mutations as causes of neonatal diabetes in man. Cell Metab 2014; 19:146.</a></li><li><a class="nounderline abstract_t">De Franco E, Watson RA, Weninger WJ, et al. A Specific CNOT1 Mutation Results in a Novel Syndrome of Pancreatic Agenesis and Holoprosencephaly through Impaired Pancreatic and Neurological Development. Am J Hum Genet 2019; 104:985.</a></li><li><a class="nounderline abstract_t">Kruszka P, Berger SI, Weiss K, et al. A CCR4-NOT Transcription Complex, Subunit 1, CNOT1, Variant Associated with Holoprosencephaly. Am J Hum Genet 2019; 104:990.</a></li><li><a class="nounderline abstract_t">Besser RE, Flanagan SE, Mackay DG, et al. Prematurity and Genetic Testing for Neonatal Diabetes. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Flanagan SE, Mackay DJ, Greeley SA, et al. Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype. Diabetologia 2013; 56:218.</a></li><li><a class="nounderline abstract_t">Hermann R, Laine AP, Johansson C, et al. Transient but not permanent neonatal diabetes mellitus is associated with paternal uniparental isodisomy of chromosome 6. Pediatrics 2000; 105:49.</a></li><li><a class="nounderline abstract_t">Shield JP. Neonatal diabetes: new insights into aetiology and implications. Horm Res 2000; 53 Suppl 1:7.</a></li><li><a class="nounderline abstract_t">Kamiya M, Judson H, Okazaki Y, et al. The cell cycle control gene ZAC/PLAGL1 is imprinted--a strong candidate gene for transient neonatal diabetes. Hum Mol Genet 2000; 9:453.</a></li><li><a class="nounderline abstract_t">Temple IK, Shield JP. Transient neonatal diabetes, a disorder of imprinting. J Med Genet 2002; 39:872.</a></li><li><a class="nounderline abstract_t">Mackay DJ, Callaway JL, Marks SM, et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet 2008; 40:949.</a></li><li><a class="nounderline abstract_t">Aguilar-Bryan L, Bryan J. Neonatal diabetes mellitus. Endocr Rev 2008; 29:265.</a></li><li><a class="nounderline abstract_t">Garin I, Edghill EL, Akerman I, et al. Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis. Proc Natl Acad Sci U S A 2010; 107:3105.</a></li><li><a class="nounderline abstract_t">Mackay DJ, Temple IK. Transient neonatal diabetes mellitus type 1. Am J Med Genet C Semin Med Genet 2010; 154C:335.</a></li><li><a class="nounderline abstract_t">Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467.</a></li><li><a class="nounderline abstract_t">Landau Z, Wainstein J, Hanukoglu A, et al. Sulfonylurea-responsive diabetes in childhood. J Pediatr 2007; 150:553.</a></li><li><a class="nounderline abstract_t">Carmody D, Bell CD, Hwang JL, et al. Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab 2014; 99:E2709.</a></li><li><a class="nounderline abstract_t">Babiker T, Vedovato N, Patel K, et al. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes. Diabetologia 2016; 59:1162.</a></li><li><a class="nounderline abstract_t">Mohamadi A, Clark LM, Lipkin PH, et al. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM. Pediatr Diabetes 2010; 11:203.</a></li><li><a class="nounderline abstract_t">Carmody D, Pastore AN, Landmeier KA, et al. Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls. Diabet Med 2016; 33:1380.</a></li><li><a class="nounderline abstract_t">Bowman P, Broadbridge E, Knight BA, et al. Psychiatric morbidity in children with KCNJ11 neonatal diabetes. Diabet Med 2016; 33:1387.</a></li><li><a class="nounderline abstract_t">Landmeier KA, Lanning M, Carmody D, et al. ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes. Pediatr Diabetes 2017; 18:518.</a></li><li><a class="nounderline abstract_t">Bowman P, Hattersley AT, Knight BA, et al. Neuropsychological impairments in children with KCNJ11 neonatal diabetes. Diabet Med 2017; 34:1171.</a></li><li><a class="nounderline abstract_t">Annamalai SK, Arunachalam KD. Uranium (238U) bioaccumulation and its persuaded alterations on hematological, serological and histological parameters in freshwater fish Pangasius sutchi. Environ Toxicol Pharmacol 2017; 52:262.</a></li><li><a class="nounderline abstract_t">Shah RP, Spruyt K, Kragie BC, et al. Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas. Diabetes Care 2012; 35:2086.</a></li><li><a class="nounderline abstract_t">Letourneau LR, Greeley SAW. Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations. Curr Diab Rep 2019; 19:52.</a></li><li><a class="nounderline abstract_t">Svalastoga P, Sulen Å, Fehn JR, et al. Intellectual Disability in KATP Channel Neonatal Diabetes. Diabetes Care 2020; 43:526.</a></li><li><a class="nounderline abstract_t">Akerman I, Maestro MA, De Franco E, et al. Neonatal diabetes mutations disrupt a chromatin pioneering function that activates the human insulin gene. Cell Rep 2021; 35:108981.</a></li><li><a class="nounderline abstract_t">Semple RK, Savage DB, Cochran EK, et al. Genetic syndromes of severe insulin resistance. Endocr Rev 2011; 32:498.</a></li><li><a class="nounderline abstract_t">Slingerland AS, Hattersley AT. Activating mutations in the gene encoding Kir6.2 alter fetal and postnatal growth and also cause neonatal diabetes. J Clin Endocrinol Metab 2006; 91:2782.</a></li><li><a class="nounderline abstract_t">Hammoud B, Greeley SAW. Growth and development in monogenic forms of neonatal diabetes. Curr Opin Endocrinol Diabetes Obes 2022; 29:65.</a></li><li><a class="nounderline abstract_t">Winter WE, Maclaren NK, Riley WJ, et al. Congenital pancreatic hypoplasia: a syndrome of exocrine and endocrine pancreatic insufficiency. J Pediatr 1986; 109:465.</a></li><li><a class="nounderline abstract_t">Baumeister FA, Engelsberger I, Schulze A. Pancreatic agenesis as cause for neonatal diabetes mellitus. Klin Padiatr 2005; 217:76.</a></li><li><a class="nounderline abstract_t">Shaw-Smith C, Flanagan SE, Patch AM, et al. Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia. Pediatr Diabetes 2012; 13:314.</a></li><li><a class="nounderline abstract_t">Stanescu DE, Hughes N, Patel P, De León DD. A novel mutation in GATA6 causes pancreatic agenesis. Pediatr Diabetes 2015; 16:67.</a></li><li><a class="nounderline abstract_t">Shalev SA, Tenenbaum-Rakover Y, Horovitz Y, et al. Microcephaly, epilepsy, and neonatal diabetes due to compound heterozygous mutations in IER3IP1: insights into the natural history of a rare disorder. Pediatr Diabetes 2014; 15:252.</a></li><li><a class="nounderline abstract_t">Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005; 54:2503.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 Suppl 1:S62.</a></li><li><a class="nounderline abstract_t">Hwang MJ, Newman R, Philla K, Flanigan E. Use of Insulin Glargine in the Management of Neonatal Hyperglycemia in an ELBW Infant. Pediatrics 2018; 141:S399.</a></li><li><a class="nounderline abstract_t">Passanisi S, Timpanaro T, Lo Presti D, et al. Treatment of transient neonatal diabetes mellitus: insulin pump or insulin glargine? Our experience. Diabetes Technol Ther 2014; 16:880.</a></li><li><a class="nounderline abstract_t">Romano F, Tinti D, Spada M, et al. Neonatal diabetes in a patient with IPEX syndrome: an attempt at balancing insulin therapy. Acta Diabetol 2017; 54:1139.</a></li><li><a class="nounderline abstract_t">Beardsall K, Pesterfield CL, Acerini CL. Neonatal diabetes and insulin pump therapy. Arch Dis Child Fetal Neonatal Ed 2011; 96:F223.</a></li><li><a class="nounderline abstract_t">Bharucha T, Brown J, McDonnell C, et al. Neonatal diabetes mellitus: Insulin pump as an alternative management strategy. J Paediatr Child Health 2005; 41:522.</a></li><li><a class="nounderline abstract_t">Park JH, Shin SY, Shim YJ, et al. Multiple daily injection of insulin regimen for a 10-month-old infant with type 1 diabetes mellitus and diabetic ketoacidosis. Ann Pediatr Endocrinol Metab 2016; 21:96.</a></li><li><a class="nounderline abstract_t">Garcin L, Mericq V, Fauret-Amsellem AL, et al. Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype. Pediatr Diabetes 2020; 21:932.</a></li><li><a class="nounderline abstract_t">Thurber BW, Carmody D, Tadie EC, et al. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia 2015; 58:1430.</a></li></ol></div><div id="topicVersionRevision">Topic 116267 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24051999" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diabetes mellitus in neonates and infants: genetic heterogeneity, clinical approach to diagnosis, and therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26231457" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29406006" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neonatal Diabetes Mellitus: An Update on Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28779000" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diabetes Presentation in Infancy: High Risk of Diabetic Ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20546293" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15115830" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292329" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15448107" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885549" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20148032" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rfx6 directs islet formation and insulin production in mice and humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11372010" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neonatal diabetes mellitus due to complete glucokinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18451997" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855560" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Insulin gene mutations as a cause of permanent neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162506" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20938745" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10932183" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185226" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Autopsy findings in the Wolcott-Rallison syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220213" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20738327" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Wolfram syndrome and WFS1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29193502" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : FOXP3 mutations causing early-onset insulin-requiring diabetes but without other features of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038750" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29305528" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Erratum. Recessively Inherited LRBA Mutations Cause Autoimmunity Presenting as Neonatal Diabetes. Diabetes 2017;66:2316-2322.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988180" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9649577" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Insulin promoter factor-1 gene mutation linked to early-onset type 2 diabetes mellitus directs expression of a dominant negative isoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15543146" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutations in PTF1A cause pancreatic and cerebellar agenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16715098" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20854389" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Genetic investigation in an Italian child with an unusual association of atrial septal defect, attributable to a new familial GATA4 gene mutation, and neonatal diabetes due to pancreatic agenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20573748" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21490072" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Neonatal diabetes and congenital malabsorptive diarrhea attributable to a novel mutation in the human neurogenin-3 gene coding sequence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181075" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Neonatal diabetes mellitus and neonatal polycystic, dysplastic kidneys: Phenotypically discordant recurrence of a mutation in the hepatocyte nuclear factor-1beta gene due to germline mosaicism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756345" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : PAX6 mutation as a genetic factor common to aniridia and glucose intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24411943" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Analysis of transcription factors key for mouse pancreatic development establishes NKX2-2 and MNX1 mutations as causes of neonatal diabetes in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31006513" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A Specific CNOT1 Mutation Results in a Novel Syndrome of Pancreatic Agenesis and Holoprosencephaly through Impaired Pancreatic and Neurological Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31006510" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A CCR4-NOT Transcription Complex, Subunit 1, CNOT1, Variant Associated with Holoprosencephaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27540106" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prematurity and Genetic Testing for Neonatal Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111732" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10617703" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Transient but not permanent neonatal diabetes mellitus is associated with paternal uniparental isodisomy of chromosome 6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10895036" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neonatal diabetes: new insights into aetiology and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655556" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The cell cycle control gene ZAC/PLAGL1 is imprinted--a strong candidate gene for transient neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12471198" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transient neonatal diabetes, a disorder of imprinting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18622393" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436707" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neonatal diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20133622" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20803656" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Transient neonatal diabetes mellitus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885550" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452235" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sulfonylurea-responsive diabetes in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25238204" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27033559" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19686306" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27223594" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086753" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Psychiatric morbidity in children with KCNJ11 neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27555491" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477417" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neuropsychological impairments in children with KCNJ11 neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477471" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Uranium (238U) bioaccumulation and its persuaded alterations on hematological, serological and histological parameters in freshwater fish Pangasius sutchi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22855734" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31250216" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31932458" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intellectual Disability in KATP Channel Neonatal Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33852861" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neonatal diabetes mutations disrupt a chromatin pioneering function that activates the human insulin gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536711" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Genetic syndromes of severe insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636122" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Activating mutations in the gene encoding Kir6.2 alter fetal and postnatal growth and also cause neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34864759" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Growth and development in monogenic forms of neonatal diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3746536" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Congenital pancreatic hypoplasia: a syndrome of exocrine and endocrine pancreatic insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15770578" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pancreatic agenesis as cause for neonatal diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22369132" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433315" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A novel mutation in GATA6 causes pancreatic agenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24138066" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Microcephaly, epilepsy, and neonatal diabetes due to compound heterozygous mutations in IER3IP1: insights into the natural history of a rare disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123337" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042775" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diagnosis and classification of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610159" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Use of Insulin Glargine in the Management of Neonatal Hyperglycemia in an ELBW Infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25437016" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of transient neonatal diabetes mellitus: insulin pump or insulin glargine? Our experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28988367" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Neonatal diabetes in a patient with IPEX syndrome: an attempt at balancing insulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115555" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Neonatal diabetes and insulin pump therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150072" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Neonatal diabetes mellitus: Insulin pump as an alternative management strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27462587" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Multiple daily injection of insulin regimen for a 10-month-old infant with type 1 diabetes mellitus and diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32418263" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25877689" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
